Cargando…
Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma
Malignant mesothelioma is an aggressive cancer with limited therapeutic options. Sialic acid-binding lectin isolated from Rana catesbeiana oocytes (cSBL) is a multifunctional protein with anti-cancer activity. The effects of pemetrexed, cisplatin, and cSBL were evaluated in mesothelioma and normal m...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522080/ https://www.ncbi.nlm.nih.gov/pubmed/28476017 http://dx.doi.org/10.18632/oncotarget.17198 |
_version_ | 1783252095346933760 |
---|---|
author | Satoh, Toshiyuki Tatsuta, Takeo Sugawara, Shigeki Hara, Akiyoshi Hosono, Masahiro |
author_facet | Satoh, Toshiyuki Tatsuta, Takeo Sugawara, Shigeki Hara, Akiyoshi Hosono, Masahiro |
author_sort | Satoh, Toshiyuki |
collection | PubMed |
description | Malignant mesothelioma is an aggressive cancer with limited therapeutic options. Sialic acid-binding lectin isolated from Rana catesbeiana oocytes (cSBL) is a multifunctional protein with anti-cancer activity. The effects of pemetrexed, cisplatin, and cSBL were evaluated in mesothelioma and normal mesothelial cell lines. We evaluated cytotoxicity, apoptosis, caspase-3 cleavage and activation, cell proliferation, cell cycle arrest, and levels of cell cycle proteins in H28 cells treated with pemetrexed, cisplatin, and cSBL alone or in combination. Treatment with cSBL alone was cytotoxic to mesothelioma cells. The anti-cancer effect of cSBL was observed in a broader range of cell lines and exhibited greater cancer cell selectivity than pemetrexed or cisplatin. Combination treatment with pemetrexed + cSBL resulted in greater dose-dependent cytotoxicity than pemetrexed + cisplatin, the standard of care in mesothelioma. The synergistic effect of pemetrexed + cSBL was mediated by the cytostatic effect of pemetrexed and the cytotoxic effect of cSBL. It thus appears that cSBL has therapeutic potential for the treatment of mesothelioma. |
format | Online Article Text |
id | pubmed-5522080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55220802017-08-08 Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma Satoh, Toshiyuki Tatsuta, Takeo Sugawara, Shigeki Hara, Akiyoshi Hosono, Masahiro Oncotarget Research Paper Malignant mesothelioma is an aggressive cancer with limited therapeutic options. Sialic acid-binding lectin isolated from Rana catesbeiana oocytes (cSBL) is a multifunctional protein with anti-cancer activity. The effects of pemetrexed, cisplatin, and cSBL were evaluated in mesothelioma and normal mesothelial cell lines. We evaluated cytotoxicity, apoptosis, caspase-3 cleavage and activation, cell proliferation, cell cycle arrest, and levels of cell cycle proteins in H28 cells treated with pemetrexed, cisplatin, and cSBL alone or in combination. Treatment with cSBL alone was cytotoxic to mesothelioma cells. The anti-cancer effect of cSBL was observed in a broader range of cell lines and exhibited greater cancer cell selectivity than pemetrexed or cisplatin. Combination treatment with pemetrexed + cSBL resulted in greater dose-dependent cytotoxicity than pemetrexed + cisplatin, the standard of care in mesothelioma. The synergistic effect of pemetrexed + cSBL was mediated by the cytostatic effect of pemetrexed and the cytotoxic effect of cSBL. It thus appears that cSBL has therapeutic potential for the treatment of mesothelioma. Impact Journals LLC 2017-04-18 /pmc/articles/PMC5522080/ /pubmed/28476017 http://dx.doi.org/10.18632/oncotarget.17198 Text en Copyright: © 2017 Satoh et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Satoh, Toshiyuki Tatsuta, Takeo Sugawara, Shigeki Hara, Akiyoshi Hosono, Masahiro Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma |
title | Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma |
title_full | Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma |
title_fullStr | Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma |
title_full_unstemmed | Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma |
title_short | Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma |
title_sort | synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522080/ https://www.ncbi.nlm.nih.gov/pubmed/28476017 http://dx.doi.org/10.18632/oncotarget.17198 |
work_keys_str_mv | AT satohtoshiyuki synergisticantitumoreffectofbullfrogsialicacidbindinglectinandpemetrexedinmalignantmesothelioma AT tatsutatakeo synergisticantitumoreffectofbullfrogsialicacidbindinglectinandpemetrexedinmalignantmesothelioma AT sugawarashigeki synergisticantitumoreffectofbullfrogsialicacidbindinglectinandpemetrexedinmalignantmesothelioma AT haraakiyoshi synergisticantitumoreffectofbullfrogsialicacidbindinglectinandpemetrexedinmalignantmesothelioma AT hosonomasahiro synergisticantitumoreffectofbullfrogsialicacidbindinglectinandpemetrexedinmalignantmesothelioma |